Associations of statin use with glycaemic traits and incident type 2 diabetes.

Ahmadizar, Fariba; OchoaRosales, Carolina; Glisic, Marja; Franco, Oscar H; Muka, Taulant; Stricker, Bruno H (2019). Associations of statin use with glycaemic traits and incident type 2 diabetes. British journal of clinical pharmacology, 85(5), pp. 993-1002. Wiley-Blackwell 10.1111/bcp.13898

Preview	Text Ahmadizar BrJClinPharmacol 2019_AAM.pdf - Accepted Version Available under License Publisher holds Copyright. Download (587kB) | Preview
	Text Ahmadizar BrJClinPharmacol 2019.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (843kB) | Request a copy

AIMS

There are several epidemiological studies on the association between statins and incident diabetes, but most of them lack details. In this study, we aimed to investigate the association of statin use with glycaemic traits and incident type 2 diabetes.

METHODS

Using the prospective population-based Rotterdam Study, we included 9,535 individuals free from diabetes at baseline (>45 years) during the study period between 1997 and 2012. Linear regression analysis was applied to examine the cross-sectional associations between statin use and glycaemic traits including fasting blood serum of glucose and insulin concentrations, and insulin resistance. In a longitudinal follow-up study, we applied a Cox regression analysis to determine adjusted hazard ratios (HR) for incident type 2 diabetes in new users of statins.

RESULTS

The mean age at baseline was 64.3±10.1 year and 41.7% were men. In the fully adjusted model, compared to never users of statins, baseline use of statins was associated with higher concentrations of serum fasting insulin (β, 0.07; 95% CI: 0.02-0.13) and insulin resistance (β, 0.09; 95% CI: 0.03-0.14). Ever use of statins was associated with a 38% higher risk of incident type 2 diabetes (HR, 1.38; 95% CI: 1.09-1.74). This risk was more prominent in subjects with impaired glucose homeostasis and in overweight/obese individuals.

CONCLUSIONS

Individuals using statins may be at higher risk for hyperglycaemia, insulin resistance and eventually type 2 diabetes. Rigorous preventive strategies such as glucose control and weight reduction in patients when initiating statin therapy might help minimizing the risk of diabetes.

Interest & Impact

Downloads

80 since deposited on 13 Mar 2019
27 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item